Vincent Xiang

Managing Partner and Founder

2021 - Current

Board Member

2018

Advisor

2017

Co-Founder

2013

Managing Director, Head of Global BioVenture

2018 - 2020

Partner

2016 - 2018

1. A lean and well experienced team focusing on cross border life science investments 2. An expanding fund ($1.6B AUM) agnostic to stage, size, and sector 3. A superb track record in growth with entrepreneurs and return to investors 4. An outcome driven, sharing and caring culture for all stakeholders Please join us for an exciting ride to impact sea changes in global healthcare! W. Vincent Xiang, PhD, MBA vincent.xiang@frontlinebioventures.com 1 805 4058658 cell

Managing Director, Head of International Investments and Business Development

2013 - 2016

Humanwell Group (人福医药集团）is a fast growing, midcap medical product company with global largecap ambition. It is one of the top life science companies in China, publicly listed in China with annual revenue of ~$1B in 2012. Humanwell is specialized in development, production, distribution and technical support of pharmaceutical, medical instrument, and reproductive healthcare products. It has deep technical resources and pharmaceutical development capability. 57 drug production lines at 6 subsidiaries have been certificated by the National Food and Drug Administration (CFDA) according to GMP standards. Humanwell has established powerful ethic drug and OTC marketing networks, and chain of pharmacies. Its 3 drug sales subsidiaries have obtained GSP-certified business licenses from CFDA. From 2006 to 2012, Humanwell’s operation revenue has grown at annual growth rate of 38.6%, double that of industry average. We have over 2500 professional sales representatives covering 10000 hospitals and 30000 pharmacies. If you are looking for maximizing the value of your drugs, devices, or tools at various stages, Humanwell is the partner of choice in and outside of China. We welcome you with our expertise along the entire value chain.

Managing Director, China

2011 - 2012

- Foster technology and market innovations in China healthcare industry - Screened over 100 life science companies in China for potential private equity investment - Work with strategic partners for fund formation and long term collaboration - Advise entrepreneurs on value creation, business development and financial management

VP, Portfolio Manager, Analyst

2004 - 2011

- Investment in global life science companies at all stages - Bottom-up fundamental analysis and investment for best in the class life science/technology, value proposition, and value protection - Created financial models, scenario analysis, and due diligence process; Invested in best in class companies such as Pharmacyclics, Pharmion, Celgene, Genentech, Onyx and OSI - Invested in Chinese healthcare firms such as 3S Bio, BMP Sunstone and Omnitura (Private); Screened and analyzed > 60 Chinese private and public life science firms - Advised Chinese entrepreneurs on business development and financial management

VP of Business Development

2003 - 2004

- Led due diligence, market research, strategic planning, and out- / in- licensing deal sourcing for the biotech startup - Raised fund through equity financing and partnership